Update on pediatric pulmonary arterial hypertension

Area of Science:

• Pediatric Cardiology
• Pulmonary Hypertension Research
• Medical Therapeutics

Background:

• Pulmonary arterial hypertension (PAH) presents a significant health challenge in children, leading to severe illness and death.
• The 2018 World Symposium redefined pulmonary hypertension (PH) criteria, setting mean pulmonary artery pressure above 20 mmHg for adults and children.

Purpose of the Study:

• To review recent advancements in the diagnosis and treatment of pediatric pulmonary arterial hypertension.
• To highlight the impact of new therapeutic strategies on outcomes for children with PAH.

Main Methods:

• Review of recent scientific literature and clinical findings.
• Analysis of updated diagnostic criteria and therapeutic approvals for PAH.
• Examination of the use of advanced imaging and clinical monitoring in risk stratification.

Main Results:

• Improved risk stratification for pulmonary hypertension patients through advanced imaging and clinical monitoring.
• Increased use of targeted PAH therapies, with bosentan being the first FDA-approved targeted therapy for pediatric use in 2017.
• Off-label use of adult-approved therapies in pediatric patients has led to better outcomes.

Conclusions:

• Recent advancements in diagnosis and the introduction of novel therapies have improved the outlook for children with pulmonary arterial hypertension.
• The updated definition of pulmonary hypertension and targeted therapies mark significant progress in managing pediatric PAH.